Linlin Li

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Antitumor efficacy and safety of locoregional [177Lu]Lu-RM26 radionuclide therapy in glioblastoma.

Antitumor efficacy and safety of locoregional [177Lu]Lu-RM26 radionuclide therapy in glioblastoma.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 15, 2026

Phase separation of TRNAU1AP protein sustains selenoprotein translation and promotes glioblastoma tumorigenesis.

Phase separation of TRNAU1AP protein sustains selenoprotein translation and promotes glioblastoma tumorigenesis.

Journal: Neuro-oncology
Published: November 11, 2025

[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11.

[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11.

Journal: European journal of nuclear medicine and molecular imaging
Published: September 18, 2025

Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies.

Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies.

Journal: Clinical nuclear medicine
Published: January 14, 2025

Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer: A Comparison With [68Ga]Ga-PSMA-11 PET/CT.

Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer: A Comparison With [68Ga]Ga-PSMA-11 PET/CT.

Journal: Clinical nuclear medicine
Published: December 18, 2024

Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study.

Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study.

Journal: Clinical nuclear medicine
Published: February 02, 2023

USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.

USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.

Journal: Neuro-oncology
Published: October 14, 2022

Critical role of lncEPAT in coupling dysregulated EGFR pathway and histone H2A deubiquitination during glioblastoma tumorigenesis.

Critical role of lncEPAT in coupling dysregulated EGFR pathway and histone H2A deubiquitination during glioblastoma tumorigenesis.

Journal: Science advances
Published: October 05, 2022

The Roles and Regulation of m6A Modification in Glioblastoma Stem Cells and Tumorigenesis.

The Roles and Regulation of m6A Modification in Glioblastoma Stem Cells and Tumorigenesis.

Journal: Biomedicines
Published: March 18, 2022
Showing 1-9 of 9

Last Updated: 09/26/2026